Exclusive: Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO
The Wellcome Sanger Institute’s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the helm and $28 million in Series A funds.
Called Mosaic Therapeutics, the startup is working on new targeted treatments from the labs of Sanger’s Mathew Garnett and Sanofi board member Emile Voest, who works at the Netherlands Cancer Institute and Oncode Institute. Also on the co-founding team is former Sanger head of technology translation Adrian Ibrahim.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.